Irrespectively of KRAS-status, Zoledronic acid reduced migratory capacity of all the applied NSCLC lines, which suggests the inhibition of other small G proteins involved in motility signal (such as Rho, Rac, Cdc42) by preventing posttranslational prenylation. Here, KRAS is linked to non-small cell lung carcinoma.